Week Ending June 13, 2022

Navigating to earlier detection of lung cancer
“Building on the success of our Lung Cancer Screening program, the McLeod Health team has been detecting lung cancer earlier and saving lives through low-dose CT scans for more than seven years. Since that time the cancer team has expanded the program to include four dedicated nurse navigators, a lung nodule clinic and patient conferences with multiple specialists.”

First-Line Toripalimab Plus Chemotherapy Elicits Survival Benefit in NSCLC Irrespective of PD-L1 Status
“Adding toripalimab (Tuoyi) to chemotherapy in the frontline setting demonstrated improved progression-free survival (PFS) vs placebo plus chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) without EGFR or ALK mutations, regardless of PD-L1 status, according to a biomarker analysis of the phase 3 CHOICE-01 trial (NCT03856411).1

The Link Between Lung Cancer and Depression
“Cancer is a disease that occurs when some cells in the body grow out of control and spread to other parts of the body, causing damage. Lung cancer is a type of cancer that begins in the lungs, but it can spread and affect other areas of the body, as well.”

Pioneering new targeted treatments
UC team studies role of lipids in lung cancer growth
“Researchers at the University of Cincinnati are studying how a specific gene and fatty acids, called lipids, help fortify lung cancer cells and if targeting the gene and lipids can lead to better outcomes for patients.”

Durable Responses Continue with Keytruda Plus Chemoradiation in Previously Untreated Non-Small Cell Lung Cancer
“Treatment with Keytruda (pembrolizumab) plus concurrent chemoradiation followed by Keytruda monotherapy continues to be effective after two years in patients with previously untreated, locally advanced stage 3 non–small cell lung cancer (NSCLC), according to updated study findings.”

Lung-MAP: Post-immunotherapy ramucirumab plus pembrolizumab improves NSCLC survival
“Ramucirumab plus pembrolizumab significantly improves overall survival (OS) versus standard of care in people with advanced non-small-cell lung cancer (NSCLC) previously treated with immunotherapy and chemotherapy, phase 2 Lung-MAP Protocol substudy data show.”

Lorlatinib in Frontline Therapy for ALK+ Advanced Non–Small-Cell Lung Cancer: Still a Matter of Debate?
“Anaplastic lymphoma kinase (ALK) gene rearrangement is probably the oncogenic addiction in thoracic oncology for which we have made the most progress in just over 10 years, demonstrating the ability of precision medicine to transform the natural history of diseases that initially depend on a single genomic alteration.”

Plant compound effective against lung cancer in laboratory setting
“Lung cancer is the second most common type of cancer in the world. There were more than 2.2 million new diagnoses of lung cancer around the world in 2020. And that same year, globally about 1.8 million people died from lung cancer.”

Study links SARS-CoV-2 specific T cells with inflammation and reduced lung function in long COVID
“A new study published in today’s issue of PLoS Pathogens is the first to link SARS-CoV-2 specific T cells to lung function and those who suffer from long-term COVID symptoms (PASC). Long-covid currently affects hundreds of millions of Americans.”